Data / Research funding / Malaria Vaccine
Malaria Vaccine: 144 NIH awards ($216M) to 62 organizations
144 NIH awards ($216M) in the NIH spending category Malaria Vaccine, to 62 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
144 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Computational models of naturally acquired immunity to falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,666,873 | April 1, 2020 | March 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Inducing durable, protective immune memory against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,488,192 | January 16, 2019 | December 31, 2023 | KAPPE, STEFAN HI | reporter.nih.gov |
| Structure and function of the Plasmodium myosin XIV-actin glideosome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,384,780 | May 11, 2017 | June 30, 2027 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,285,014 | July 1, 2025 | June 30, 2028 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,209,021 | June 17, 2020 | May 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Systems biological assessment of vaccination-induced protective immunity in African children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,984 | February 1, 2022 | January 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Progressing PfSPZ vaccines for malaria to licensure and commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,994,338 | April 14, 2023 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,935,817 | July 1, 2016 | June 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A universal malaria T cell vaccine based on HLA-E presentation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,934,908 | May 20, 2022 | April 30, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,925,300 | May 17, 2018 | June 30, 2025 | KHUONG, NHI | reporter.nih.gov |
| Automating mosquito microdissection for a malaria PfSPZ vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,924,306 | June 20, 2017 | April 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Defining targets of protective immunity to vivax malaria using human monoclonal antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,825,320 | March 24, 2020 | February 28, 2026 | KING, CHRISTOPHER L | reporter.nih.gov |
| Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,803,324 | March 1, 2022 | February 28, 2027 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,802,178 | May 1, 2022 | April 30, 2027 | SRINIVASAN, PRAKASH | reporter.nih.gov |
| Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine Candidates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,788,646 | August 1, 2025 | July 31, 2027 | BEI, AMY KRISTINE | reporter.nih.gov |
| Collective Responses to Malaria Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,779,001 | February 9, 2022 | January 31, 2027 | STUART, KENNETH D | reporter.nih.gov |
| Harnessing the Malarial Immunity Omics Landscape in Vaccinated and Unvaccinated Children for Improved Therapeutic Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,743,704 | July 1, 2025 | June 30, 2029 | PERKINS, DOUGLAS JAY | reporter.nih.gov |
| Defining conserved epitopes on polymorphic malaria antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,726,813 | February 19, 2021 | January 31, 2027 | BUNNIK, EVELIEN MARGARETHA | reporter.nih.gov |
| Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,600,040 | March 8, 2022 | February 28, 2027 | YAZDANBAKHSH, MARIA | reporter.nih.gov |
| A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,501,040 | September 30, 2023 | September 29, 2028 | TSUJI, MORIYA | reporter.nih.gov |
| Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,467,626 | January 1, 2019 | December 31, 2023 | SATHER, D. NOAH | reporter.nih.gov |
| Immunity to Liver-stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,414,340 | January 12, 2022 | January 14, 2025 | HARTY, JOHN T | reporter.nih.gov |
| Liver resident memory for malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,368,344 | November 23, 2018 | October 31, 2024 | MURPHY, SEAN C | reporter.nih.gov |
| Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,110,841 | January 15, 2019 | December 31, 2024 | CARNEIRO DA SILVA, JOANA | reporter.nih.gov |
| The role of natural killer cells and antibodies in protection from malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,108,688 | March 25, 2020 | February 28, 2026 | HART, GEOFFREY T | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,065,107 | August 23, 2023 | July 31, 2027 | MILICH, DAVID R. | reporter.nih.gov |
| Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,755 | December 8, 2023 | November 30, 2026 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,973,577 | February 15, 2004 | June 30, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Cryopreservation of Anopheles Embryos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,928,928 | August 1, 2010 | January 31, 2024 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,917,896 | July 5, 2024 | May 31, 2029 | SWEARINGEN, KRISTIAN EDWARD | reporter.nih.gov |
| In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,912,715 | February 15, 2010 | May 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Type-I Interferons drive cell-autonomous immunity to malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,887,500 | June 21, 2022 | May 31, 2027 | KURUP, SAM | reporter.nih.gov |
| Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,841,511 | November 9, 2022 | October 31, 2027 | CHACKERIAN, BRYCE C | reporter.nih.gov |
| Immunological characterization of the P. vivax DBP | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,773,948 | August 1, 2006 | March 31, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| DISCOVERY AND PRECLINICAL DEVELOPMENT OF EFFICACIOUS P. vivax PRE-ERYTHROCYTIC STAGE MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,745,498 | November 20, 2020 | October 31, 2023 | HERRERA VALENCIA, SOCRATES | reporter.nih.gov |
| Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,631,717 | May 20, 2020 | April 30, 2026 | LOVELL, JONATHAN F | reporter.nih.gov |
| Identification & Evaluation of Novel Malaria Anti-Gametocyte Transmission Blocking Vaccine Candidate Antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,594,902 | August 29, 2019 | July 31, 2025 | NIXON, CHRISTIAN PARCHER | reporter.nih.gov |
| Mechanisms of compromised CD8 T cell responses to vaccination in malaria experienced hosts | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,507,165 | June 24, 2024 | April 30, 2029 | HARTY, JOHN T | reporter.nih.gov |
| Multivalent mRNA-based malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,456,890 | August 1, 2024 | July 31, 2029 | BURNS, JAMES MATTHEW | reporter.nih.gov |
| Exploiting cross-reactive, conserved epitopes in Plasmodium vivax to develop a vaccine against falciparum placental malaria. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,453,074 | March 10, 2020 | February 28, 2027 | YANOW, STEPHANIE | reporter.nih.gov |
| Structural Vaccinology and Design of Novel Imunogens for Malaria Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,430,568 | February 1, 2018 | January 31, 2024 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Human-informed data-driven development of next-generation T cell vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,424,256 | September 2, 2022 | August 31, 2026 | DOOLAN, DENISE L. | reporter.nih.gov |
| Impacts of Environment, Host Genetics and Antigen Diversity on Malaria Vaccine Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,363,169 | March 1, 2018 | February 28, 2025 | BAILEY, JEFFREY A. | reporter.nih.gov |
| Impact of early childhood malaria prevention on malaria risk at school entry (ERASE) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,276,157 | July 10, 2024 | May 31, 2029 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,256,250 | April 1, 2014 | April 30, 2025 | BUCALA, RICHARD J | reporter.nih.gov |
| Multi-target blood stage vaccine against Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,107,549 | December 13, 2019 | November 30, 2026 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $988,772 | September 1, 2022 | June 30, 2024 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Serological markers of natural immunity to Plasmodium falciparum infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $858,047 | July 12, 2021 | January 23, 2026 | FRIEDMAN-KLABANOFF, DEANNA | reporter.nih.gov |
| Species-transcending prevention of mosquito vector infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $832,071 | November 14, 2024 | October 31, 2029 | SATHER, D. NOAH | reporter.nih.gov |
| mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $813,160 | December 26, 2024 | November 30, 2029 | KUMAR, NIRBHAY | reporter.nih.gov |
| The function of atypical B cells in the immune response against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $812,704 | January 3, 2025 | December 31, 2026 | BUNNIK, EVELIEN MARGARETHA | reporter.nih.gov |
| A systems analysis to understand the differential pharmacokinetics and protective efficacy of anti-malarial monoclonal antibodies in field trials. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $781,241 | August 5, 2025 | July 31, 2030 | TRAN, TUAN MANH | reporter.nih.gov |
| Mentoring in patient-oriented research in global health | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $759,276 | January 11, 2016 | July 31, 2027 | LAUFER, MIRIAM K. | reporter.nih.gov |
| Identifying the targets of protective immunity to severe falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $708,202 | December 20, 2024 | November 30, 2029 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Malaria vaccine evaluation in a novel infant NHP challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $706,000 | November 4, 2022 | October 31, 2025 | SHEARS, MELANIE JANET | reporter.nih.gov |
| Discovery and preclinical evaluation of Plasmodium falciparum and P. vivax coiled coil antigens for malaria vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $702,029 | January 3, 2020 | December 31, 2022 | HERRERA VALENCIA, SOCRATES | reporter.nih.gov |
| Exploring the roles of acquired immunity and functional constraint in sculpting malaria antigenic diversity in a longitudinal cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $694,822 | September 25, 2018 | October 31, 2024 | NEAFSEY, DANIEL E | reporter.nih.gov |
| Determinants of poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $690,500 | December 6, 2024 | November 30, 2029 | VALIM, CLARISSA | reporter.nih.gov |
| Impact of early-life pathogen exposures on pre-erythrocytic malaria vaccine effectiveness in Kenyan infants | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $682,200 | August 22, 2025 | July 31, 2030 | DOBBS, KATHERINE ROSE | reporter.nih.gov |
| Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $668,302 | August 11, 2017 | July 31, 2023 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Enhancing T and B cell responses to Plasmodium infection and vaccination via IL-15 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $606,767 | June 20, 2024 | April 30, 2025 | BURRACK, KRISTINA STOERMER | reporter.nih.gov |
| Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $600,000 | April 12, 2021 | March 31, 2024 | JAMES, ERIC ROBERT | reporter.nih.gov |
| In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $600,000 | June 3, 2022 | May 31, 2025 | SIM, B. KIM LEE | reporter.nih.gov |
| Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $599,951 | February 14, 2023 | January 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $599,740 | June 1, 2024 | May 31, 2027 | ANTHONY, KAREN G. | reporter.nih.gov |
| The Development and Function of Plasmodium-specific memory B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $596,609 | December 16, 2016 | November 30, 2022 | PEPPER, MARION | reporter.nih.gov |
| Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $586,904 | August 12, 2019 | July 31, 2024 | FROSCH, ANNE ELIZABETH PARKER | reporter.nih.gov |
| The Germinal Center and T cell help in Three Phases of Clearance of Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $564,054 | November 1, 2017 | July 15, 2022 | STEPHENS, ROBIN | reporter.nih.gov |
| Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $559,942 | September 6, 2023 | August 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Directed in vivo assembly of a robust biopolymer particle-based multistage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $549,032 | September 10, 2025 | August 31, 2028 | REHM, BERND | reporter.nih.gov |
| Antigen discovery for transmission-blocking vaccines in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $540,000 | April 6, 2020 | February 28, 2025 | CAO, YAMING | reporter.nih.gov |
| The Skin Phase of Malaria Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $536,335 | July 6, 2017 | June 30, 2024 | SINNIS, PHOTINI | reporter.nih.gov |
| Evaluating the impact of pre-existing humoral immunity on hepatocyte death | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $516,175 | June 23, 2025 | May 31, 2027 | KAUSHANSKY, ALEXIS | reporter.nih.gov |
| Identifying the targets of protective immunity to severe falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $500,144 | September 4, 2023 | August 31, 2024 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Human-informed data-driven development of next-generation T cell vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $495,904 | September 2, 2022 | January 1, 2023 | DOOLAN, DENISE L. | reporter.nih.gov |
| Generating a novel dual stage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $485,375 | September 24, 2021 | August 31, 2023 | PEPPER, MARION | reporter.nih.gov |
| Multiplex analysis of IgA and IgG antibody responses to early childhood malaria infections to inform vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $482,617 | May 2, 2023 | April 30, 2026 | BERRY, ANDREA | reporter.nih.gov |
| A Chemical Vaccine for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $473,670 | September 19, 2019 | August 31, 2023 | SHAPIRO, THERESA A | reporter.nih.gov |
| Designing a diversity-covering multiantigen multi-strain malaria vaccine | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $457,659 | August 2, 2019 | July 31, 2025 | OUATTARA, AMED | reporter.nih.gov |
| Effect of gut microbiota composition on malaria vaccine-induced immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $449,728 | June 24, 2024 | April 30, 2026 | SCHMIDT, NATHAN | reporter.nih.gov |
| Developing a barcoded malaria parasite panel to assess broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,625 | June 29, 2022 | November 30, 2024 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Investigating gene regulatory networks in immune cells of children who differ in susceptibility to malaria infection using single-cell approaches | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $432,218 | January 1, 2021 | June 30, 2024 | TRAN, TUAN MANH | reporter.nih.gov |
| High throughput chemoenzymatic synthesis of antimalarial compounds | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $429,000 | September 1, 2022 | August 31, 2025 | NARAYAN, ALISON | reporter.nih.gov |
| Design and Evaluation of a Plasmodium vivax ultra-dense peptide array | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | March 15, 2021 | February 28, 2023 | SERRE, DAVID | reporter.nih.gov |
| Intracellular-acting antibodies for the prevention of malaria liver stage infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,500 | November 4, 2022 | October 31, 2024 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Integrating a pre-erythrocytic component into a multistage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $416,125 | November 12, 2020 | October 31, 2023 | BURNS, JAMES MATTHEW | reporter.nih.gov |
| Longitudinal Antibody Profiles Correlated with Protection from Malaria in Malawi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $415,919 | January 8, 2021 | December 31, 2023 | VALIM, CLARISSA | reporter.nih.gov |
| Evaluation of Immunodominant fragments of PfGARP for malaria vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $412,500 | July 3, 2025 | June 30, 2027 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| Multi-target blood stage vaccine against Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $406,250 | December 13, 2019 | November 30, 2021 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| Anopheles FBG: a novel malaria transmission-blocking vaccine target | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $384,730 | November 8, 2022 | October 31, 2025 | LI, JUN | reporter.nih.gov |
| Impact of P. falciparum diversity on transmission reducing immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $382,428 | July 1, 2018 | June 30, 2024 | COHEE, LAUREN M | reporter.nih.gov |
| Synthesizing immunoinformatics and genetic epidemiology to identify signatures of natural functional immunity to malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $369,354 | March 1, 2023 | February 29, 2028 | MARKWALTER, CHRISTINE | reporter.nih.gov |
| Development of novel malaria pre-erythrocytic vaccine antigens targeting Plasmodium sporozoite liver infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $368,224 | January 4, 2023 | December 31, 2025 | CHA, SUNG-JAE | reporter.nih.gov |
| Large Scale systematic priorization of Plasmodium vivax blood stage vaccine antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $318,040 | February 14, 2018 | January 31, 2023 | RAYNER, JULIAN CHARLES | reporter.nih.gov |
| Mathematical modeling of immune response to malaria | NIH | National Institute of General Medical Sciences | 2021 | $303,690 | March 1, 2017 | February 28, 2023 | GANUSOV, VITALY V. | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | April 21, 2020 | March 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,994 | August 17, 2020 | July 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| PfAg, a multivalent peptide vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,954 | September 15, 2025 | August 31, 2027 | CHUANG, YU-MIN | reporter.nih.gov |
| A vaccine targeting mosquito metabolic pathways to eradicate malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,644 | September 23, 2025 | August 31, 2027 | CHUANG, YU-MIN | reporter.nih.gov |
| E. coli platform for expression of low-cost malaria fusion proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $297,809 | January 1, 2024 | June 30, 2025 | LEES, ANDREW | reporter.nih.gov |
| Safety, immunogencity, and efficacy of PfSPZ LARC2 malaria vaccine in malaria-exposed adults and children | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $250,796 | June 12, 2024 | May 31, 2025 | LAURENS, MATTHEW BRENT | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $248,674 | April 1, 2003 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| Role of cytolytic ZEB2+ memory CD4+ T cells in protection against liver stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $244,440 | January 14, 2025 | December 31, 2026 | LAUVAU, GREGOIRE STEPHANE | reporter.nih.gov |
| Biological Equivalence of In Vitro Plasmodium falciparum Culture for Practical Malaria Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $217,162 | September 21, 2020 | August 31, 2023 | AVRIL, MARION | reporter.nih.gov |
| Investigating Plasmodium vaccination in 'dirty' mice | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $205,125 | November 13, 2024 | October 31, 2026 | BURRACK, KRISTINA STOERMER | reporter.nih.gov |
| Pan-vaccine Analysis to Test the Impact of Cytomegalovirus on Vaccine Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $201,875 | June 1, 2020 | May 31, 2022 | HU, ZICHENG | reporter.nih.gov |
| Systems Antibody Immunology of the Malaria Sporozoite Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $195,480 | January 16, 2024 | August 31, 2024 | HERMAN, JONATHAN DAVID | reporter.nih.gov |
| Systems Antibody Immunology of the Malaria Sporozoite Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $195,480 | January 16, 2024 | December 31, 2028 | HERMAN, JONATHAN DAVID | reporter.nih.gov |
| Determining the mechanism of antibody-mediated parasite clearance in Plasmodium blood stage infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,438 | April 1, 2020 | March 31, 2022 | HART, GEOFFREY T | reporter.nih.gov |
| Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approaches | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $185,224 | February 10, 2017 | January 31, 2023 | TRAN, TUAN MANH | reporter.nih.gov |
| Modulation of Monocyte and T Cell Functions by Immune Inhibitory Receptors during Subclinical Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $184,109 | December 19, 2024 | November 30, 2026 | DOBBS, KATHERINE ROSE | reporter.nih.gov |
| Exploring the parasite genomics of severe falciparum malaria in Mozambique | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $183,677 | March 5, 2020 | February 28, 2023 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Hemozoin and liver stage malaria vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $183,276 | August 1, 2025 | July 31, 2027 | HASSERT, MARIAH A | reporter.nih.gov |
| Protein microarray antibody responses to P. falciparum in a human challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $183,004 | February 6, 2017 | January 31, 2024 | BERRY, ANDREA | reporter.nih.gov |
| Determinants of Vaccine Responses in Low-Income Countries (LICs) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $176,738 | September 1, 2025 | August 31, 2030 | VALIM, CLARISSA | reporter.nih.gov |
| Group 1 CD1-restricted human T cells induced by a whole sporozoite-based malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $162,000 | March 10, 2020 | February 28, 2022 | TSUJI, MORIYA | reporter.nih.gov |
| Validation and characterization of antibody responses to Plasmodium falciparum antigens identified by protein array screening | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $158,500 | February 10, 2021 | January 31, 2024 | TRAN, TUAN MANH | reporter.nih.gov |
| Understanding and overcoming Plasmodium-specific immune evasion mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $156,980 | June 1, 2024 | May 31, 2026 | MCDOUGAL, COURTNEY | reporter.nih.gov |
| Design of a B cell tetramer to track PfMSP2-specific B cells | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $152,000 | November 1, 2021 | October 31, 2023 | STUMHOFER, JASON S | reporter.nih.gov |
| Modeling mutant PfCRT-mediated drug transport to predict the emergence of piperaquine-resistant Plasmodium falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $140,482 | January 1, 2021 | December 31, 2023 | HAGENAH, LAURA MARIE | reporter.nih.gov |
| The Kinetics and Dynamics of Functional Immune Responses to Plasmodium falciparum Strains | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $83,460 | July 1, 2024 | June 30, 2027 | HAGADORN, KELLY | reporter.nih.gov |
| Analyzing the function and antibody-mediated inhibition of the malaria vaccine candidate PF3D7_1136200 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $81,086 | August 1, 2024 | September 22, 2027 | GARZA, ROLANDO | reporter.nih.gov |
| Employing Genetic and Genomic Surveillance to Reveal Mechanisms of Malaria Parasite Persistance | NIH | Fogarty International Center | 2021 | $73,070 | September 28, 2016 | December 31, 2022 | BEI, AMY KRISTINE | reporter.nih.gov |
| Defining molecular and cellular mechanisms of protection from malaria infection by PfCSP-targeting antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $66,390 | June 15, 2021 | June 14, 2022 | MARTIN, GREGORY M | reporter.nih.gov |
| Improving the Translational Potential of a Prime-and-Trap Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $54,332 | September 10, 2022 | September 11, 2023 | WATSON, FELICIA | reporter.nih.gov |
| Molecular and cellular properties of broad and protective immune responses to the Plasmodium falciparum variant surface antigen responsible for severe malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $45,919 | May 1, 2022 | June 2, 2023 | REYES, RAPHAEL ANTHONY | reporter.nih.gov |
| Dissecting compromised efficacy of liver-stage malaria immunizations in hosts with a history of blood-stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $26,156 | July 28, 2022 | December 2, 2022 | DREWRY, LISA L | reporter.nih.gov |
| Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $25,001 | March 3, 2020 | February 28, 2023 | FERRARI, GUIDO | reporter.nih.gov |
| Development of novel malaria pre-erythrocytic vaccine antigens targeting Plasmodium sporozoite liver infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $24,188 | January 4, 2023 | March 17, 2023 | CHA, SUNG-JAE | reporter.nih.gov |
| Malaria: Mechanisms of Immunity & Protection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $7,500 | January 23, 2025 | December 31, 2025 | SHEPPARD, TERRY L. | reporter.nih.gov |
| 2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $5,000 | August 22, 2023 | July 31, 2024 | WEINER, DAVID B. | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 63 | $38,804,706 | 0 | $0 |
| 2024 | 63 | $39,019,021 | 0 | $0 |
| 2023 | 71 | $42,254,483 | 0 | $0 |
| 2022 | 72 | $47,236,942 | 0 | $0 |
| 2021 | 70 | $48,683,001 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 139 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 139 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 139 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.